Abstract:Background. Ductal carcinoma in situ (DCIS) has become a non-negligible part of breast cancers owing to the greatly increased incidence. While its natural history was not fully elucidated, which is the reason for current controversies in clinical treatment. Exploration of this issue from a clinical perspective is meaningful. Methods. Medical records of 389 patients diagnosed with DCIS or DCIS with invasive ductal carcinoma (IDC) were reviewed. All of them received appropriate medical care in our center. All 324 patients in training cohort were divided into invasion and non-invasion groups based on pathology. Differences in DCIS immunohistochemical markers and hematological indicators between them were analyzed. In the invasion group, differences between DCIS and matched IDC were compared to explore changes in the tumor heterogeneity during invasion. Conclusions are validated in the validation cohort of 65 patients. Results. Patients in invasion and non-invasion groups were balanced in baseline characteristics and no statistically significant differences were noticed for DCIS immunohistochemical markers. For hematological indicators, high expression of platelet > 291.50) (odds ratio, 2.46; CI [1.35-4.46]; p = 0.003) and SII (> 347.20) (odds ratio, 2.54; CI [1.56-4.12]; p < 0.001) were established as independent predictors for invasion by logistic analysis and were validated in the validation cohort. Ki-67 of IDC was significantly higher than that of matched DCIS (p < 0.001). HER2 expression and histological grade of DCIS were separately linearly related to those of IDC. Conclusion. The change in hematological indicators is an independent predictor for invasion and can be incorporated into the treatment decision-making process for DCIS. Invasion tumor cells exhibit a stronger proliferative capacity compared with the in-situ ones. There are linear relationships in HER2 expression and histological grades between DCIS and matched IDC. DCIS subclones with different histological grades will develop into invasive carcinomas separately.

Clinical practice guidelines for ductal carcinoma in situ: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

Clinicopathological Features of Breast Cancer Progression: from DCIS to Invasive Ductal Carcinoma

Introduction to the Key Contents of the Chinese Society of Breast Surgery Practice Guideline 2021

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

To establish high-quality clinical practice guidelines and promote the standardization of diagnosis and treatment of breast disease in China

Clinicopathologic features and treatment of ductal carcinoma in situ of the breast]

Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients

Breast Ductal Carcinoma in Situ with Microinvasion: Clinicopathological Characteristics, Prognosis and Role of Surgery in Treatment

Diagnosis and Treatment of Ductal Carcinoma in Situ:Report of 371 Cases

Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021

Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion

Ductal Carcinoma in Situ of Breast: from Molecular Etiology to Therapeutic Management

Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022

[Chinese Expert Consensus on the Diagnosis and Treatment of Breast Carcinoma in Situ].

Treatment Trends and Prognosis of Breast Ductal Carcinoma in Situ: a Single Center Analysis

Risk Factors for Lymph Node Metastasis and the Impact of Adjuvant Chemotherapy on Ductal Carcinoma in Situ with Microinvasion: a Population-Based Study.

Laying equal stress on research and clinical guidelines to promote the development of breast surgery in China

An insight into the invasion of breast ductal carcinoma <i>in situ</i> based on clinical, pathological and hematological data

Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It?

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment